Publication

Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of the Dopamine D-2 Receptor Occupancy of Olanzapine in Rats

Johnson, M., Kozielska, M., Reddy, V. P., Vermeulen, A., Li, C., Grimwood, S., de Greef, R., Groothuis, G. M. M., Danhof, M. & Proost, J. H., Oct-2011, In : Pharmaceutical Research. 28, 10, p. 2490-2504 15 p.

Research output: Contribution to journalArticleAcademicpeer-review

A mechanism-based PK-PD model was developed to predict the time course of dopamine D-2 receptor occupancy (D2RO) in rat striatum following administration of olanzapine, an atypical antipsychotic drug.

A population approach was utilized to quantify both the pharmacokinetics and pharmacodynamics of olanzapine in rats using the exposure (plasma and brain concentration) and D2RO profile obtained experimentally at various doses (0.01-40 mg/kg) administered by different routes. A two-compartment pharmacokinetic model was used to describe the plasma pharmacokinetic profile. A hybrid physiology- and mechanism-based model was developed to characterize the D-2 receptor binding in the striatum and was fitted sequentially to the data. The parameters were estimated using nonlinear mixed-effects modeling .

Plasma, brain concentration profiles and time course of D2RO were well described by the model; validity of the proposed model is supported by good agreement between estimated association and dissociation rate constants and in vitro values from literature.

This model includes both receptor binding kinetics and pharmacokinetics as the basis for the prediction of the D2RO in rats. Moreover, this modeling framework can be applied to scale the in vitro and preclinical information to clinical receptor occupancy.

Original languageEnglish
Pages (from-to)2490-2504
Number of pages15
JournalPharmaceutical Research
Volume28
Issue number10
Publication statusPublished - Oct-2011

    Keywords

  • antipsychotic, dopamine D-2 receptor occupancy, koff, mechanism-based PK-PD, olanzapine, translational model, BLOOD-BRAIN-BARRIER, IN-VIVO, ATYPICAL ANTIPSYCHOTICS, P-GLYCOPROTEIN, DRUG DISPOSITION, BINDING, VITRO, PHARMACOKINETICS/PHARMACODYNAMICS, BUPRENORPHINE, PERMEABILITY

View graph of relations

ID: 5398915